Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$45.32
-4.3%		$33.45
$11.27
▼
$49.76
$2.34B2.391.21 million shs708,767 shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$74.13
+0.9%		$79.27
$35.22
▼
$88.31
$9.22B0.381.89 million shs1.76 million shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$57.24
+2.5%		$65.62
$41.71
▼
$86.74
$9.51B0.412.90 million shs1.35 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$155.10
+2.4%		$129.77
$54.18
▼
$155.53
$10.04B1.78511,582 shs426,259 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-4.35%-2.93%+52.34%+126.94%+273.62%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.93%-3.43%-10.28%-2.27%+100.79%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
+2.45%+1.20%+4.59%-22.89%+32.81%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+2.43%+6.33%+14.50%+51.79%+173.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$45.32
-4.3%		$33.45
$11.27
▼
$49.76
$2.34B2.391.21 million shs708,767 shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$74.13
+0.9%		$79.27
$35.22
▼
$88.31
$9.22B0.381.89 million shs1.76 million shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$57.24
+2.5%		$65.62
$41.71
▼
$86.74
$9.51B0.412.90 million shs1.35 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$155.10
+2.4%		$129.77
$54.18
▼
$155.53
$10.04B1.78511,582 shs426,259 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-4.35%-2.93%+52.34%+126.94%+273.62%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.93%-3.43%-10.28%-2.27%+100.79%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
+2.45%+1.20%+4.59%-22.89%+32.81%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+2.43%+6.33%+14.50%+51.79%+173.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CareDx, Inc. stock logo
CDNA
CareDx
2.57
Moderate Buy$47.755.36% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.86
Moderate Buy$102.2037.87% Upside
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.77
Moderate Buy$94.6565.36% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2.94
Moderate Buy$137.86-11.12% Downside

Current Analyst Ratings Breakdown

Latest CDNA, CYTK, IONS, and PTGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/13/2026
CareDx, Inc. stock logo
CDNA
CareDx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C)
8/13/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$95.00 ➝ $110.00
8/13/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$97.00 ➝ $103.00
8/11/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C+)
8/10/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $170.00
8/10/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$106.00 ➝ $112.00
8/10/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$118.00 ➝ $173.00
8/10/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy
8/10/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$110.00 ➝ $186.00
8/7/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$117.00 ➝ $112.00
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CareDx, Inc. stock logo
CDNA
CareDx
$379.80M6.17$0.01 per share6,957.96$8.23 per share5.51
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$88.04M104.77N/AN/A($1.39) per share-53.33
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$944M10.08N/AN/A$2.65 per share21.60
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$46.02M218.09N/AN/A$13.01 per share11.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M$2.0721.8971.94N/A24.23%2.87%2.17%11/3/2026 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$784.96M-$7.22N/AN/AN/A-1,321.12%N/A-51.01%N/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$381.39M-$3.46N/AN/AN/A-64.76%-111.08%-17.41%N/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$130.15M$1.03150.58N/AN/A29.40%12.03%11.23%N/A

Latest CDNA, CYTK, IONS, and PTGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.63-$1.50+$0.13-$1.50$17.59 million$28.62 million
8/5/2026Q2 2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$2.27$2.29+$0.02$2.29$212.03 million$213.48 million
7/30/2026Q2 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2321$0.37+$0.1379$2.07$114.05 million$131.95 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CareDx, Inc. stock logo
CDNA
CareDx
N/A
4.58
4.51
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
6.66
6.66
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
3.07
7.89
7.73
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
21.71
21.71

Institutional Ownership

CompanyInstitutional Ownership
CareDx, Inc. stock logo
CDNA
CareDx
N/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
93.86%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%

Insider Ownership

CompanyInsider Ownership
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.60%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1.81%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
5.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
CareDx, Inc. stock logo
CDNA
CareDx
74051.73 million50.49 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250124.43 million121.20 millionOptionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,402166.18 million163.18 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12064.71 million61.35 millionOptionable

Recent News About These Companies

Dinesh Ph Patel Sells 65,761 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
August 14 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30960744
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 34,239 Shares of Stock
August 13 at 6:36 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ptgx-insider-buying-and-selling-2026-08-13/
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts
August 13 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30957626
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages
August 13 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-inc-nasdaqptgx-given-average-recommendation-of-moderate-buy-by-brokerages-2026-08-13/
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $5,085,176.28 in Stock
August 12 at 7:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-nasdaqptgx-ceo-sells-508517628-in-stock-2026-08-12/
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 65,761 Shares
August 12 at 7:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-nasdaqptgx-ceo-dinesh-ph-patel-sells-65761-shares-2026-08-12/
Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement
August 12 at 8:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4935261-protagonist-therapeutics-strong-buy-icotyde-fda-approval-and-pn-881-advancement
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - Here's Why
August 12 at 4:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-nasdaqptgx-reaches-new-1-year-high-heres-why-2026-08-12/
Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/silence-therapeutics-apos-divesiran-data-150540332.html
Protagonist Therapeutics Inc.
August 11, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/ptgx/financials
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
August 11, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972688/4-psoriasis-drug-stocks-to-watch-during-psoriasis-awareness-month-2026?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2972688
Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/wedbush-adjusts-pt-protagonist-therapeutics-112200970.html
What is HC Wainwright's Estimate for PTGX FY2026 Earnings?
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951332
HC Wainwright Has Negative Forecast for PTGX FY2026 Earnings
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-negative-forecast-for-ptgx-fy2026-earnings-2026-08-10/
HC Wainwright Analysts Decrease Earnings Estimates for PTGX
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949229
Citigroup Raises Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $175.00
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30948374
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High on Earnings Beat
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947988
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Wall Street Zen to Buy
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947579
Protagonist Therapeutics (NASDAQ:PTGX) Rating Lowered to Buy at Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-nasdaqptgx-rating-lowered-to-buy-at-wall-street-zen-2026-08-08/
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971270/surging-earnings-estimates-signal-upside-for-protagonist-therapeutics-ptgx-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_8-2971270
HC Wainwright Has Negative Forecast for PTGX Q3 Earnings
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-negative-forecast-for-ptgx-q3-earnings-2026-08-07/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
First Internet Bancorp logo illuminated on a glass panel beside a bank card and smartphone with financial charts.
System Upgrade: First Internet Bancorp Options Surge
By Jeffrey Neal Johnson | August 4, 2026
Military drone aircraft flying over a mountainous desert landscape at sunset.
3 Drone Stocks That Should Soar After the Summer Slump
By Chris Markoch | August 4, 2026
Apple logo illuminated on a dark surface beside the edge of a smartphone with visible camera lenses.
Apple’s Record Quarter Could Not Outrun Its Guidance Problem
By Sam Quirke | July 31, 2026
CareDx stock logo

CareDx NASDAQ:CDNA

$45.32 -2.06 (-4.35%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$45.58 +0.26 (+0.56%)
As of 08/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$74.13 +0.68 (+0.93%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$74.13 0.00 (0.00%)
As of 08/14/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$57.24 +1.37 (+2.45%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$56.12 -1.12 (-1.96%)
As of 08/14/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$155.10 +3.68 (+2.43%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$155.06 -0.03 (-0.02%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas